MX2019011808A - Endolisinas de gram-negativas modificadas. - Google Patents
Endolisinas de gram-negativas modificadas.Info
- Publication number
- MX2019011808A MX2019011808A MX2019011808A MX2019011808A MX2019011808A MX 2019011808 A MX2019011808 A MX 2019011808A MX 2019011808 A MX2019011808 A MX 2019011808A MX 2019011808 A MX2019011808 A MX 2019011808A MX 2019011808 A MX2019011808 A MX 2019011808A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- relates
- bacteriophages
- vectors
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
La presente invención se refiere en general al campo de las enzimas antimicrobianas. En particular, la presente invención se refiere a un polipéptido que comprende la secuencia de aminoácidos de una endolisina globular de Gramnegativas y la secuencia de aminoácidos de un dominio de unión a la pared celular de i) una endolisina modular de Gram-negativas o ii) una proteína de la cola/placa base de un bacteriófago. La presente invención también se refiere a los ácidos nucleicos, vectores, bacteriófagos, células huésped y composiciones correspondientes. La presente invención también se refiere al uso de dichos polipéptidos, ácidos nucleicos, vectores, bacteriófagos, células huésped y composiciones en procedimientos para el tratamiento del cuerpo humano o animal mediante cirugía o terapia o en procedimientos de diagnóstico practicados en el cuerpo humano o animal. Los polipéptidos, ácidos nucleicos, vectores, bacteriófagos, células huésped y composiciones de acuerdo con la invención también se pueden utilizar como un antimicrobiano en, por ejemplo, alimentos o piensos, en cosméticos, o como un agente desinfectante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2017051886 | 2017-04-03 | ||
| PCT/IB2018/052253 WO2018185634A1 (en) | 2017-04-03 | 2018-04-02 | Engineered gram-negative endolysins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019011808A true MX2019011808A (es) | 2020-01-09 |
Family
ID=58547758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019011808A MX2019011808A (es) | 2017-04-03 | 2018-04-02 | Endolisinas de gram-negativas modificadas. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11208643B2 (es) |
| EP (1) | EP3607062A1 (es) |
| JP (2) | JP2020515295A (es) |
| KR (2) | KR20240162610A (es) |
| CN (1) | CN110651044A (es) |
| AU (1) | AU2018248060B2 (es) |
| CA (1) | CA3059019A1 (es) |
| IL (1) | IL269442A (es) |
| MX (1) | MX2019011808A (es) |
| SG (1) | SG11201908657VA (es) |
| WO (1) | WO2018185634A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3464583A1 (en) * | 2016-05-27 | 2019-04-10 | Sasinapas Co., Ltd. | Endolysin variant |
| CN120136980A (zh) * | 2019-05-08 | 2025-06-13 | 生物技术公司 | 新的加德纳菌内溶素及其用途 |
| CN112724257B (zh) * | 2019-10-14 | 2023-09-19 | 江西缘生生物科技有限公司 | 具有强杀菌效果的杂合抗菌蛋白及其应用 |
| MX2022011291A (es) * | 2020-03-11 | 2022-12-08 | Telum Therapeutics S L | Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. |
| CN115702242A (zh) * | 2020-04-20 | 2023-02-14 | 医药控股公司 | 一种改性的细菌透明质酸酶多肽、生产方法、药物组合物及其用途 |
| WO2021235876A1 (ko) | 2020-05-22 | 2021-11-25 | 주식회사 라이센텍 | 신규한 폴리펩타이드, 융합 폴리펩타이드, 및 이를 포함하는 그람음성균에 대한 항생제 |
| CN114478794A (zh) * | 2020-11-13 | 2022-05-13 | 江苏万邦医药科技有限公司 | 幽门螺旋杆菌噬菌体裂解系统及其表达纯化方法和应用 |
| KR20230024845A (ko) | 2021-08-09 | 2023-02-21 | 주식회사 레고켐 바이오사이언스 | 신규 항생제 및 이의 용도 |
| CN113801864B (zh) * | 2021-08-13 | 2023-09-26 | 青岛农业大学 | 一种用于编码溶酶菌lysin6的基因及其应用 |
| US12102667B2 (en) * | 2021-08-19 | 2024-10-01 | Lysentech Co., Ltd. | Polypeptides and antibiotics against gram-negative bacterium comprising the same |
| CN116144633B (zh) * | 2021-11-19 | 2024-12-06 | 中国农业科学院生物技术研究所 | 一种改构鸡蛋清溶菌酶及其应用 |
| US11548917B1 (en) * | 2021-11-24 | 2023-01-10 | Intron Biotechnology, Inc. | Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same |
| CN116410329A (zh) * | 2021-12-30 | 2023-07-11 | 上海高科生物工程有限公司 | 一种c末端修饰的杂合抗菌蛋白及其药物组合物和应用 |
| CN115851690B (zh) * | 2022-10-08 | 2025-02-11 | 昆山博青生物科技有限公司 | 一种用于杀灭动物源病原菌的杂合抗生酶及其应用 |
| CN116083406B (zh) * | 2022-12-02 | 2025-03-25 | 凯莱英生命科学技术(天津)有限公司 | 酰胺酶突变体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8816693D0 (en) | 1988-07-13 | 1988-08-17 | Agricultural & Food Res | Viral enzyme & gene |
| DK2037946T3 (en) * | 2006-05-05 | 2015-04-27 | Gangagen Inc | ANTIMICROBIAL ACTIVITIES DERIVED BY PHAGER |
| EP2157100A1 (en) * | 2008-08-19 | 2010-02-24 | Profos AG | Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins |
| GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| DK2445515T3 (en) * | 2009-06-26 | 2016-07-04 | Univ Leuven Kath | antimicrobial agents |
| KR101701890B1 (ko) * | 2009-06-26 | 2017-02-02 | 뤼산도 아게 | 항균제 |
| EP2468856A1 (en) * | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
| CN103635584B (zh) * | 2011-04-12 | 2017-10-27 | 冈戈根股份有限公司 | 嵌合抗菌多肽 |
| WO2015070911A1 (en) * | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified kz144 endolysin sequence |
| WO2015070912A1 (en) * | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified el188 endolysin sequence |
-
2018
- 2018-04-02 AU AU2018248060A patent/AU2018248060B2/en not_active Ceased
- 2018-04-02 WO PCT/IB2018/052253 patent/WO2018185634A1/en not_active Ceased
- 2018-04-02 MX MX2019011808A patent/MX2019011808A/es unknown
- 2018-04-02 US US16/500,163 patent/US11208643B2/en active Active
- 2018-04-02 CN CN201880023776.1A patent/CN110651044A/zh active Pending
- 2018-04-02 KR KR1020247037449A patent/KR20240162610A/ko active Pending
- 2018-04-02 KR KR1020197032549A patent/KR20200012844A/ko not_active Ceased
- 2018-04-02 SG SG11201908657V patent/SG11201908657VA/en unknown
- 2018-04-02 EP EP18718639.0A patent/EP3607062A1/en not_active Withdrawn
- 2018-04-02 CA CA3059019A patent/CA3059019A1/en active Pending
- 2018-04-02 JP JP2020503382A patent/JP2020515295A/ja active Pending
-
2019
- 2019-09-18 IL IL26944219A patent/IL269442A/en unknown
-
2021
- 2021-11-17 US US17/529,246 patent/US20220064616A1/en not_active Abandoned
-
2023
- 2023-02-17 JP JP2023023005A patent/JP2023062086A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018248060B2 (en) | 2024-05-23 |
| JP2023062086A (ja) | 2023-05-02 |
| CN110651044A (zh) | 2020-01-03 |
| KR20240162610A (ko) | 2024-11-15 |
| AU2018248060A1 (en) | 2019-10-03 |
| US20210108185A1 (en) | 2021-04-15 |
| SG11201908657VA (en) | 2019-10-30 |
| US11208643B2 (en) | 2021-12-28 |
| EP3607062A1 (en) | 2020-02-12 |
| WO2018185634A1 (en) | 2018-10-11 |
| CA3059019A1 (en) | 2018-10-11 |
| IL269442A (en) | 2019-11-28 |
| KR20200012844A (ko) | 2020-02-05 |
| US20220064616A1 (en) | 2022-03-03 |
| JP2020515295A (ja) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011808A (es) | Endolisinas de gram-negativas modificadas. | |
| MX2012002216A (es) | Nueva endolisina obpgplys. | |
| EA201270079A1 (ru) | Антимикробные агенты | |
| MX2019005979A (es) | Peptidos modificados. | |
| BR112013010844A2 (pt) | nova endolisina | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| MX2021009696A (es) | Vectores de genoterapia para el tratamiento de la enfermedad de danon. | |
| WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
| MX2011013453A (es) | Agentes antimicrobianos. | |
| WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
| MX2021000401A (es) | Nuevas proteinas de fusion especificas para cd137 y pd-l1. | |
| BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
| MX2021014601A (es) | Proteinas recombinantes de union a fap y su uso. | |
| WO2017125585A3 (en) | Novel polypeptides and medical uses thereof | |
| MX2020006098A (es) | Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano. | |
| UY33047A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| EA202192555A1 (ru) | Комбинированная терапия для лечения рака | |
| MX2020000018A (es) | Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos. | |
| BR112021024822A2 (pt) | Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência | |
| MY189334A (en) | Lentiviral vector-based japanese encephalitis immunogenic composition | |
| EP4570317A3 (en) | Compounds for the treatment of bovine or swine respiratory disease | |
| MX2017008567A (es) | Dnasa modificada y usos de la misma. | |
| MX2020010932A (es) | Enzimas quinureninasa humanas y sus usos. | |
| MX2019000235A (es) | Eliminacion de la cistina mediada por enzimas humanas. | |
| CU24746B1 (es) | Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular |